Christopher Peetz
Oprichter bij MIRUM PHARMACEUTICALS, INC.
Vermogen: 8 M $ op 30-04-2024
Actieve functies van Christopher Peetz
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
MIRUM PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 01-11-2018 | - |
Algemeen Directeur | 21-03-2019 | - | |
Oprichter | 07-05-2018 | - | |
President | 01-11-2018 | 16-01-2024 | |
Satiogen Pharmaceuticals, Inc.
Satiogen Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Satiogen Pharmaceuticals, Inc. engages in the development of therapeutic treatments for diabetes and obesity. It offers a metabolic mechanism for treating diabetes and obesity without intervention by systemically absorbed pharmaceuticals or invasive surgical methods. The firm’s product strategies include non-absorbed ASBT inhibitor, non-surgical biliary shunt, rectal satiogen, non-absorbed TGR5 ligand and labile bile acid sequestrant. The company was founded by Andrew Young and Bronislava Gedulin in 2007 and is headquartered in Del Mar, CA. | Algemeen Directeur | - | - |
Loopbaan van Christopher Peetz
Eerdere bekende functies van Christopher Peetz
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ALPINE IMMUNE SCIENCES, INC. | Directeur/Bestuurslid | 24-04-2018 | 20-05-2024 |
Independent Dir/Board Member | 24-04-2018 | 20-05-2024 | |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Financieel Directeur/CFO | 01-05-2014 | 01-12-2016 |
TOBIRA THERAPEUTICS INC | Financieel Directeur/CFO | 01-05-2014 | 01-12-2016 |
Flashlight Therapeutics, Inc.
Flashlight Therapeutics, Inc. BiotechnologyHealth Technology Flashlight Therapeutics, Inc. develops therapeutics for unmet medical needs. | Algemeen Directeur | 01-05-2017 | 01-12-2019 |
SillaJen Biotherapeutics, Inc.
SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01-04-2012 | 01-03-2014 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | 01-01-2007 | 01-01-2012 |
TERRAVIA HOLDINGS INC | Corporate Officer/Principal | - | - |
Opleiding van Christopher Peetz
Washington University in St. Louis | Undergraduate Degree |
Stanford Graduate School of Business | Masters Business Admin |
Statistieken
Internationaal
Verenigde Staten | 12 |
Operationeel
Chief Executive Officer | 3 |
Corporate Officer/Principal | 3 |
Director of Finance/CFO | 2 |
Sectoraal
Health Technology | 7 |
Commercial Services | 3 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
ALPINE IMMUNE SCIENCES, INC. | Health Technology |
MIRUM PHARMACEUTICALS, INC. | Health Technology |
Bedrijven in privébezit | 7 |
---|---|
SillaJen Biotherapeutics, Inc.
SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Commercial Services |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
TerraVia Holdings, Inc.
TerraVia Holdings, Inc. Household/Personal CareConsumer Non-Durables TerraVia Holdings, Inc. engaged in the production of food, nutrition, and specialty ingredients from algae. It produced oils, specialty fats, and powdered ingredients using its microalgae-based technology platform. The company was founded by Jonathan S. Wolfson and Harrison F. Dillon on March 31, 2003 and was headquartered in San Francisco, CA. | Consumer Non-Durables |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Health Technology |
Tobira Therapeutics, Inc.
Tobira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company was founded on October 6, 2006 and is headquartered in Madison, NJ. | Health Technology |
Flashlight Therapeutics, Inc.
Flashlight Therapeutics, Inc. BiotechnologyHealth Technology Flashlight Therapeutics, Inc. develops therapeutics for unmet medical needs. | Health Technology |
Satiogen Pharmaceuticals, Inc.
Satiogen Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Satiogen Pharmaceuticals, Inc. engages in the development of therapeutic treatments for diabetes and obesity. It offers a metabolic mechanism for treating diabetes and obesity without intervention by systemically absorbed pharmaceuticals or invasive surgical methods. The firm’s product strategies include non-absorbed ASBT inhibitor, non-surgical biliary shunt, rectal satiogen, non-absorbed TGR5 ligand and labile bile acid sequestrant. The company was founded by Andrew Young and Bronislava Gedulin in 2007 and is headquartered in Del Mar, CA. | Commercial Services |
- Beurs
- Insiders
- Christopher Peetz
- Ervaring